PubMed Health⌕ Search

Biomedical subjects

Edward Nelson

Publications and source records attributed to Edward Nelson.

3 recordsLinked to original sources

Seven-day storage of random donor PLT concentrates.

BACKGROUND: PLT concentrates are licensed for use up to a maximum of 5 days of storage. Increasing storage to 7 days would improve the logistics of supply and have the potential to reduce wastage. STUDY DESIGN AND METHODS: PLTs were prepared from CP2D blood with standard procedures (n = 16) and then WBC-reduced. Sampling was carried out at 3, 5, and 7 days for PLT count, pH, aggregation to ADP and collagen, hypotonic shock response, Kunicki morphology score, thromboelastogram response, pO2, and pCO2, and PLT activation (CD62) was carried out by flow cytometry. Additionally, PLTs stored for 7 days were transfused into thrombocytopenic patients, and the CCI was calculated. RESULTS: Some of the in vitro tests such as the aggregation response to single stimuli showed decreased values with time. The hypotonic shock was well maintained for 7 days (77%-68%); the Kunicki morphology score showed progressive shape change (300 to 164). The CCI of 7-day PLTs averaged 16,000 (n = 9). CONCLUSIONS: The data indicate acceptable in vitro PLT function at 7 days. Transfusion of the 7-day-old CP2D PLTs resulted in an appropriate posttransfusion increment in thrombocytopenic patients. Random donor PLTs collected into CP2D can be successfully stored for 7 days before use.

Blood Donors↗

Lack of economic benefit with basiliximab induction in living related donor adult renal transplant recipients.

STUDY OBJECTIVE: To assess the effect of basiliximab (BAS) induction therapy on acute rejection rates and overall costs in adult living related donor (LRD) renal transplant recipients. Design. Retrospective chart review and cost-effectiveness analysis of the first 12 months after transplantation. SETTING: University hospital and outpatient renal transplant clinic. PATIENTS: Sixty consecutive adult LRD renal transplant recipients. INTERVENTION: The treatment group received BAS 20 mg intravenously on postoperative days 0 and 4. The control group received no induction agents. Both groups received cyclosporine microemulsion, azathioprine, and corticosteroids for maintenance immunosuppression. MEASUREMENTS AND MAIN RESULTS: Six patients (three in each group) were excluded; three had received muromonab-CD3 as an induction agent and three were lost to follow-up. At 12-months, the frequency of acute rejection episodes was 15% (4/27) in the control group and 22% (6/27) in the BAS group (NS). Renal function, as measured by average serum creatinine level, was similar at months 1, 2, 3, 6, and 12 for both groups. The frequency of infectious complications was similar in both groups. No adverse effects were associated with BAS. Mean initial hospitalization charges were dollar 51,970.01 and dollar 68,093.90 in the control and BAS groups, respectively (p < 0.05). The control group had more readmissions (18 vs 14 in the BAS group), but the average charge/readmission was lower (dollar 10,148.50 vs dollar 21,952.58 in the BAS group; NS). All costs were adjusted to 2000 dollars (US). CONCLUSION: Basiliximab induction therapy did not provide clear clinical efficacy benefit or prove to be cost-effective compared with no induction in LRD recipients.

Adult↗